Dr. Constance Zou, MD

Education

- Fellowship: National Institute of Mental Health – Clinical Research in Behavioral Endocrinology
- Residency: National Institute of Mental Health (PGY-4 Residency Program) & Medical University of South Carolina – General Psychiatry
- Medical School: Yale School of Medicine

In her free time, Dr. Zou enjoys cooking, gardening, forest bathing, playing board games, and spending time with friends and family.

Conferences & Abstracts

• Zou CX, Becker JE, Phillips AT, Krumholz HM, Miller JE, Ross JS. Impact of FDAAA on Registration, Results Reporting, and Publication of Neuropsychiatric Clinical Trials Supporting FDA New Drug Approval, 2005–2014. Podium Presentation, Eighth Peer Review Congress, 2017, Chicago, IL

• Basturk O, Wei JJ, Kong J, Zou X*, Peng Y, Melamed J, Lee P. MicroRNA Expression in Androgen Independent and Metastatic Prostate Cancer. United States and Canadian Academy of Pathology Annual Meeting, 2008, Denver, CO

• Newman KK, Wang BY, Cetin N, Ye H, Zou X*, Lee P, Melamed J. Differential Steroid Hormone Expression in Renal Cell Carcinoma Subtypes. USCAP Annual Meeting, 2009, Boston, MA

• Pan LY, Wei JJ, Patwa RR, Ligr M, Jain S, Zou XY*, et al. Androgen Receptor Coactivator p44/Mep50 in Ovarian Cancer. USCAP Annual Meeting, 2010, Washington, DC

Publications

• Zou CX, Becker JE, Phillips AT, Garritano JM, et al. Registration, results reporting, and publication bias of clinical trials supporting FDA approval of neuropsychiatric drugs before and after FDAAA: a retrospective cohort study. Trials. 2018; 19(1):581

• Phillips AT, Desai NR, Zou CX, et al. Association of the FDA Amendment Act with trial registration, publication, and outcome reporting. Trials. 2017 Jul 18:333

• Segura MF, Hanniford D, Menendez S, Reavie L, Zou X*, et al. Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and MITF. Proc Natl Acad Sci U S A. 2009;106(6):1814–1819

• Li Y, Wang L, Zhang M, Melamed J, Zou X*, et al. LEF1 in androgen-independent prostate cancer: regulation of AR expression, growth, and invasion. Cancer Res. 2009;69(8):3332–3338

• Shi G, Perle MA, Mittal K, Chen H, Zou X*, et al. Let-7 repression leads to HMGA2 overexpression in uterine leiomyosarcoma. J Cell Mol Med. 2008;13(9B):3898–3905

• Peng Y, Li Y, Gellert LL, Zou X*, et al. AR coactivator p44/Mep50 in breast cancer growth and invasion. J Cell Mol Med. 2009 Oct 16

• Wang L, Zou X*, Berger AD, Twiss C, et al. Increased HDAC expression and inhibition of prostate cancer by SAHA. Am J Transl Res. 2009;1(1):62–71

• Ligr M, Li Y, Zou X*, et al. Tumor suppressor function of AR coactivator ARA70α in prostate cancer. Am J Pathol. 2010;176(4):1891–1900

• Hatcher DL, Daniels G, Lin L, Basturk O, Zou X, et al. MicroRNA and racial disparity in prostate cancer. J Urology. 2009;181(4) Suppl:773–774

• Mahajan A, Liu Z, Gellert L, Zou X*, et al. HMGA2 overexpression in high-grade ovarian serous carcinoma. Mod Pathol. 2010;23(5):673–681

• Monaco ME, Creighton CJ, Lee P, Zou X*, et al. Long-chain fatty acyl-CoA synthetase 4 and sex steroid receptor negativity in cancer. Transl Oncol. 2010;3(2):91–98

• Wu X, Chen F, Sahin A, Albarracin C, Zou X*, et al. ARA70α and β in mammary gland development and breast cancer. Breast Cancer Res Treat. 2011;128(2):391–400

Awards

• General Scholar, American Association of Geriatric Psychiatry – 2017

• Fellowship Award, National Heart, Lung, and Blood Institute, Bethesda, MD – 2016

• Mila Rainof, M.D. Memorial Scholarship, Yale School of Medicine – 2015, 2016

• Disadvantaged Merit Scholarship, Yale School of Medicine – 2015–2019

• Phi Beta Kappa, Columbia University Chapter – 2014–present

• School of General Studies Honors Society, Columbia University – 2013

• Best Thesis, China Agricultural University – 2007

• Presidential Honors Program, China Agricultural University – 2003–2007